The Conversation (0)
PropThink reported that Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) may have been overlooked as a participant in the hepatitis C market, which is worth approximately $20 billion.
PropThink reported that Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) may have been overlooked as a participant in the hepatitis C market, which is worth approximately $20 billion.
As quoted in the market news:
It is too early to count Achillion out as an important player in the [hepatitis C] market. The company’s clinical trial data is more robust than what its share price would have you believe, and the risk/reward profile is favorable. Protease inhibitors do have a role to play in the treatment of hepatitis C, and with a market capitalization of under $600 million and several upcoming catalysts, Achillion’s shares are well positioned for a rally. With several different options strategies to mitigate risk, investors can customize their positions to meet their own levels of risk-tolerance. Achillion’s best days are ahead of it, and risk-tolerant investors who add to or initiate positions in Achillion at this point in time are likely to be rewarded for their conviction.